These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10197173)

  • 1. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction.
    Osteoporos Int; 1998; 8 Suppl 4():S7-80. PubMed ID: 10197173
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence-based assessment of pharmaceutical interventions.
    Melton LJ
    Osteoporos Int; 1998; 8 Suppl 1():S17-21. PubMed ID: 9682792
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women.
    Nagata-Kobayashi S; Shimbo T; Fukui T
    J Bone Miner Metab; 2002; 20(6):350-7. PubMed ID: 12434163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ["European Guidance 2008" for the diagnosis and management of postmenopausal osteoporosis--what is new and clinically relevant?].
    Bartl R;
    Dtsch Med Wochenschr; 2009 Jan; 134(3):92-4. PubMed ID: 19142840
    [No Abstract]   [Full Text] [Related]  

  • 6. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Women's health. Osteoporosis.
    Metules T
    RN; 2003 Nov; 66(11):56-62; quiz 64. PubMed ID: 14685998
    [No Abstract]   [Full Text] [Related]  

  • 8. [Primary health care should take the initiative in fighting osteoporosis].
    Blivik J
    Lakartidningen; 2002 Feb; 99(9):876-81. PubMed ID: 11962007
    [No Abstract]   [Full Text] [Related]  

  • 9. Fracture prevention in elderly women: treatment of osteoporosis is one approach, together with physical exercise and fall prevention.
    Prescrire Int; 1998 Oct; 7(37):155-9. PubMed ID: 10915424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Staged diagnosis in osteoporosis. Is your patient at risk for fractures?].
    Seibel MJ
    MMW Fortschr Med; 2001 Nov; 143(47):26-30. PubMed ID: 11791357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Grave deficiencies in the diagnosis and therapy of osteoporosis. Expensive fracture landing].
    Wepner U
    MMW Fortschr Med; 2002 Feb; 144(7):20-1. PubMed ID: 11887727
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening and treatment in the elderly to reduce osteoporotic fracture risk.
    Black DM
    Br J Obstet Gynaecol; 1996 May; 103 Suppl 13():2-7; discussion 7-8. PubMed ID: 8624337
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results.
    Watts NB
    J Reprod Med; 2002 Jan; 47(1 Suppl):82-92. PubMed ID: 11829081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alendronate also for women without established osteoporosis?].
    Klovning A; Norheim OF
    Tidsskr Nor Laegeforen; 2000 Apr; 120(11):1347-51. PubMed ID: 10868100
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
    Jönsson L; Borgström F; Zethraeus N
    Ugeskr Laeger; 2003 Oct; 165(43):4112-6. PubMed ID: 14619061
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmaco-economic evaluation of drug therapy osteoporosis. A literature review].
    Christensen PM; Brøsen K; Brixen KT; Beck-Nielsen H; Søgaard J; Kristiansen IS
    Ugeskr Laeger; 2002 Mar; 164(10):1339-45. PubMed ID: 11894425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
    Brecht JG; Kruse HP; Felsenberg D; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2003; 23(4):93-105. PubMed ID: 15224498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
    MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
    [No Abstract]   [Full Text] [Related]  

  • 19. [Risk fractures of fracture and osteoporosis].
    Mellström D
    Lakartidningen; 2006 Oct 4-10; 103(40):2983-5. PubMed ID: 17115664
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
    Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
    Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.